Nuvation Bio Inc. (NUVB)

2.6800 +0.0600 (+2.29%) At close: 04:00PM EDT

Nuvation Bio Inc.

1500 Broadway
Suite 1401
New York, NY 10036
United States
332 208 6102
https://www.nuvationbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 51

Key executives

Name	Title	Pay	Exercised	Year born
Dr. David T. Hung M.D.	Founder, President, CEO & Director	944.51k	N/A	1958
Dr. David C. Hanley Ph.D.	Chief Technical Operations Officer	586.04k	N/A	1970
Mr. Moses Makunje	Principal Accounting Officer & Principal Financial Officer	N/A	N/A	1979
Dr. Gary Hattersley Ph.D.	Chief Scientific Officer	687.88k	N/A	1967
Ms. Stacy Markel	Chief People Officer	N/A	N/A	1965
Ms. Kerry A. Wentworth	Chief Regulatory Officer	N/A	N/A	1973
Dr. David Liu M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1970
Ms. Colleen Sjogren	Chief Commercial Officer	N/A	N/A	N/A
Dr. Junyuan Wang Ph.D.	CEO & Co-Founder of AnHeart Therapeutics and Director	N/A	N/A	1973

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Corporate governance

Nuvation Bio Inc.’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.